Very High Triglycerides News and Research

RSS
Pivotal Therapeutics enrolls first patient in POMEGA Phase IIa clinical trial of PVT-100

Pivotal Therapeutics enrolls first patient in POMEGA Phase IIa clinical trial of PVT-100

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

Omthera to be acquired by AstraZeneca

Omthera to be acquired by AstraZeneca

Isis commences ISIS-APOCIIIRx Phase 2 study in hypertriglyceridemia

Isis commences ISIS-APOCIIIRx Phase 2 study in hypertriglyceridemia

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Omthera to fund Epanova Phase 3 development with $33.9 million in Series B funding

Omthera to fund Epanova Phase 3 development with $33.9 million in Series B funding

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Positive PK study results from ECLIPSE trial against cardiovascular disease

Positive PK study results from ECLIPSE trial against cardiovascular disease

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Omthera initiates ECLIPSE study for treatment of high triglycerides

Omthera initiates ECLIPSE study for treatment of high triglycerides

CaPre drug candidate effective in managing impaired glucose tolerance

CaPre drug candidate effective in managing impaired glucose tolerance

Essentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglycerides

Essentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglycerides

Injecting apoA-V protein may reduce high triglyceride levels: Research

Injecting apoA-V protein may reduce high triglyceride levels: Research

Amarin reports cash balance of $44 million for first-quarter 2010

Amarin reports cash balance of $44 million for first-quarter 2010

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.